ADMA Biologics, Inc.
ADMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $426,454 | $258,215 | $154,080 | $80,943 |
| % Growth | 65.2% | 67.6% | 90.4% | – |
| Cost of Goods Sold | $206,901 | $169,273 | $118,815 | $79,770 |
| Gross Profit | $219,553 | $88,942 | $35,265 | $1,173 |
| % Margin | 51.5% | 34.4% | 22.9% | 1.4% |
| R&D Expenses | $1,813 | $3,300 | $3,614 | $3,646 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $74,124 | $59,020 | $52,458 | $42,897 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4,633 | $4,990 | $18,558 | $13,004 |
| Operating Expenses | $80,570 | $67,310 | $74,630 | $59,547 |
| Operating Income | $138,983 | $21,632 | -$39,365 | -$58,374 |
| % Margin | 32.6% | 8.4% | -25.5% | -72.1% |
| Other Income/Exp. Net | -$13,269 | -$49,871 | -$26,539 | -$13,274 |
| Pre-Tax Income | $125,714 | -$28,239 | -$65,904 | -$71,648 |
| Tax Expense | -$71,959 | $0 | $0 | $0 |
| Net Income | $197,673 | -$28,239 | -$65,904 | -$71,648 |
| % Margin | 46.4% | -10.9% | -42.8% | -88.5% |
| EPS | 0.85 | -0.13 | -0.43 | -0.61 |
| % Growth | 753.8% | 69.8% | 29.5% | – |
| EPS Diluted | 0.81 | -0.13 | -0.43 | -0.61 |
| Weighted Avg Shares Out | 233,084 | 223,977 | 197,875 | 139,579 |
| Weighted Avg Shares Out Dil | 243,342 | 223,977 | 197,875 | 139,579 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,097 | $1,617 | $45 | $35 |
| Interest Expense | $13,930 | $25,027 | $19,279 | $13,057 |
| Depreciation & Amortization | $8,045 | $8,332 | $7,113 | $5,496 |
| EBITDA | $147,689 | $5,120 | -$39,512 | -$53,095 |
| % Margin | 34.6% | 2% | -25.6% | -65.6% |